Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer

Anuj Khanna(University Hospitals of Leicester NHS Trust), Simon L. Parsons(Galapagos (Belgium)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), M. Cunnell(Nottingham University Hospitals NHS Trust), David J. Bowrey(University of Southern California), Alexander M. Reece-Smith(Nottingham University Hospitals NHS Trust), Anne Thomas(Leicester Royal Infirmary)

Diseases of the Esophagus

May 7, 2013

10.1111/dote.12084

Cited by 20

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

|The Lancet Oncology|2015|282